Back to top

gene-editing: Archive

Zacks Equity Research

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

VRTXNegative Net Change ACETNegative Net Change EDITPositive Net Change AKROPositive Net Change

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

VRTXNegative Net Change PBYIPositive Net Change ADMAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

RHHBYPositive Net Change SRPTNegative Net Change ADMAPositive Net Change IMCRPositive Net Change